journal article
Open Access
Mar 22, 2025
Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations
Abstract
Abstract
Traditional advanced therapies in Parkinson’s disease (PD) with motor fluctuations and dyskinesias like continuous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel (LCIG), levodopa-carbidopa entacapone intestinal gel (LECIG), or deep brain stimulation (DBS) have played a central role in managing therapy-related complications. Recently, continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) has emerged as a novel therapeutic option. This manuscript provides insights from one year of real-world experience with CSFLI, addressing critical questions that clinicians face when selecting the most appropriate therapy for advanced PD. Our discussion centers on key considerations for patient selection, exploring which individuals may benefit more from CSFLI compared to other device-aided therapies. We highlight CSFLI’s advantages in flexibility and ease of use but also consider limitations, particularly its side effects, such as skin-related issues. Recommendations are presented on how to prevent and manage these adverse effects to maximize patient compliance and therapeutic success. Additionally, the paper examines strategies for optimizing concurrent oral medications when combined with CSFLI, providing guidance on balancing pump infusion with necessary adjunctive oral treatments.
Traditional advanced therapies in Parkinson’s disease (PD) with motor fluctuations and dyskinesias like continuous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel (LCIG), levodopa-carbidopa entacapone intestinal gel (LECIG), or deep brain stimulation (DBS) have played a central role in managing therapy-related complications. Recently, continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) has emerged as a novel therapeutic option. This manuscript provides insights from one year of real-world experience with CSFLI, addressing critical questions that clinicians face when selecting the most appropriate therapy for advanced PD. Our discussion centers on key considerations for patient selection, exploring which individuals may benefit more from CSFLI compared to other device-aided therapies. We highlight CSFLI’s advantages in flexibility and ease of use but also consider limitations, particularly its side effects, such as skin-related issues. Recommendations are presented on how to prevent and manage these adverse effects to maximize patient compliance and therapeutic success. Additionally, the paper examines strategies for optimizing concurrent oral medications when combined with CSFLI, providing guidance on balancing pump infusion with necessary adjunctive oral treatments.
Topics
No keywords indexed for this article. Browse by subject →
References
129
[1]
Abboud H, Floden D, Thompson NR et al (2015) Impact of mild cognitive impairment on outcome following deep brain stimulation surgery for Parkinson’s disease. Park Relat Disord 21:249–253. https://doi.org/10.1016/j.parkreldis.2014.12.018
10.1016/j.parkreldis.2014.12.018
[2]
Acland KM, Churchyard A, Fletcher CL et al (1998) Panniculitis in association with apomorphine infusion. Br J Dermatol 138:480–482. https://doi.org/10.1046/j.1365-2133.1998.02128.x
10.1046/j.1365-2133.1998.02128.x
[3]
Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12:1937–1958. https://doi.org/10.1007/s40120-023-00533-1
10.1007/s40120-023-00533-1
[4]
Alegret M, Valldeoriola F, Martí M et al (2004) Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson’s disease. Mov Disord 19:1463–1469. https://doi.org/10.1002/mds.20237
10.1002/mds.20237
[5]
Antonini A, Isaias IU, Rodolfi G et al (2011) A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 258:579–585. https://doi.org/10.1007/s00415-010-5793-z
10.1007/s00415-010-5793-z
[6]
Antonini A, Poewe W, Chaudhuri KR et al (2017) Levodopa-carbidopa intestinal gel in advanced Parkinson’s: Final results of the GLORIA registry. Park Relat Disord 45:13–20. https://doi.org/10.1016/j.parkreldis.2017.09.018
10.1016/j.parkreldis.2017.09.018
[7]
Antonini A, Stoessl AJ, Kleinman LS et al (2018) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin 34:2063–2073. https://doi.org/10.1080/03007995.2018.1502165
10.1080/03007995.2018.1502165
[8]
Artusi CA, Geroin C, Nonnekes J et al (2023) Predictors and pathophysiology of axial postural abnormalities in parkinsonism: a scoping review. Mov Disord Clin Pr 10:1585–1596. https://doi.org/10.1002/mdc3.13879
10.1002/mdc3.13879
[9]
Barbosa ENB, Fichman HC (2019) How is cognition in subthalamic nucleus deep brain stimulation Parkinson’s disease patients? Dement Neuropsychol 13:367–377. https://doi.org/10.1590/1980-57642018dn13-040002
10.1590/1980-57642018dn13-040002
[10]
Bergquist F, Ehrnebo M, Nyholm D et al (2024) Motor efficacy of subcutaneous DIZ102, intravenous DIZ101 or intestinal levodopa/carbidopa infusion. Mov Disord Clin Pr 11:1095–1102. https://doi.org/10.1002/mdc3.14138
10.1002/mdc3.14138
[11]
Bergquist F, Ehrnebo M, Nyholm D, et al (2022) Pharmacokinetics of intravenously (DIZ101), subcutaneously (DIZ102), and intestinally (LCIG) infused levodopa in advanced parkinson disease. Neurology 99:e965–e976.https://doi.org/10.1212/WNL.0000000000200804.
10.1212/wnl.0000000000200804
[12]
Bhidayasiri R, Sringean J, Anan C et al (2016) Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson’s disease using wearable sensors. Park Relat Disord 33:S36–S41. https://doi.org/10.1016/j.parkreldis.2016.11.016
10.1016/j.parkreldis.2016.11.016
[13]
Bonuccelli U, Piccini P, Corsini GU, Muratorio A (1992) Apomorphine in malignant syndrome due to levodopa withdrawal. Ital J Neurol Sci 13:169–170. https://doi.org/10.1007/bf02226968
10.1007/bf02226968
[14]
Borgemeester RWK, Drent M, van Laar T (2016) Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson’s disease patients. Park Relat Disord 23:17–22. https://doi.org/10.1016/j.parkreldis.2015.11.013
10.1016/j.parkreldis.2015.11.013
[15]
Boura I, Haliasos N, Giannopoulou Ι et al (2021) Combining device-aided therapies in parkinson’s disease: a case series and a literature review. Mov Disord Clin Pr 8:750–757. https://doi.org/10.1002/mdc3.13228
10.1002/mdc3.13228
[16]
Bove F, Fraix V, Cavallieri F et al (2020) Dementia and subthalamic deep brain stimulation in Parkinson disease: A long-term overview. Neurology 95:e384–e392. https://doi.org/10.1212/wnl.0000000000009822
10.1212/wnl.0000000000009822
[17]
Carbone F, Djamshidian A, Seppi K, Poewe W (2019) Apomorphine for Parkinson’s Disease: efficacy and safety of current and new formulations. CNS Drugs 33:905–918. https://doi.org/10.1007/s40263-019-00661-z
10.1007/s40263-019-00661-z
[18]
Caroff SN, Jain R, Morley JF (2020) Revisiting amantadine as a treatment for drug-induced movement disorders. Ann Clin Psychiatr 32:198–208
10.1177/104012372003200309
[19]
Catalan MJ, Molina-Arjona JA, Mir P et al (2018) Improvement of impulse control disorders associated with levodopa–carbidopa intestinal gel treatment in advanced Parkinson’s disease. J Neurol 265:1279–1287. https://doi.org/10.1007/s00415-018-8803-1
10.1007/s00415-018-8803-1
[20]
Cattaneo C, Ferla RL, Bonizzoni E, Sardina M (2015) Long-term effects of safinamide on dyskinesia in mid- to late-stage parkinson’s disease: a post-hoc analysis. J Park’s Dis 5:475–481. https://doi.org/10.3233/jpd-150569
10.3233/jpd-150569
[21]
Cavallieri F, Fraix V, Bove F et al (2021) Predictors of long-term outcome of subthalamic stimulation in parkinson disease. Ann Neurol 89:587–597. https://doi.org/10.1002/ana.25994
10.1002/ana.25994
[22]
Chambi CT, Rossi M, Bril A et al (2017) Diagnostic value of combined acute levodopa challenge and olfactory testing to predict Parkinson’s disease. Mov Disord Clin Pr 4:824–828. https://doi.org/10.1002/mdc3.12517
10.1002/mdc3.12517
[23]
Chaudhuri KR, Ellis C, Love-Jones S et al (1997) Postprandial hypotension and parkinsonian state in parkinson’s disease. Mov Disord 12:877–884. https://doi.org/10.1002/mds.870120608
10.1002/mds.870120608
[24]
Chaudhuri KR, Kovács N, Pontieri FE et al (2023) Levodopa carbidopa intestinal gel in advanced Parkinson’s Disease: DUOGLOBE final 3-year results. J Park’s Dis 13:769–783. https://doi.org/10.3233/jpd-225105
10.3233/jpd-225105
[25]
Christmas TJ, Chapple CR, Lees AJ et al (1988) Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. The Lancet 332:1451–1453. https://doi.org/10.1016/s0140-6736(88)90932-4
10.1016/s0140-6736(88)90932-4
[26]
Cock VCD, Dodet P, Leu-Semenescu S et al (2022) Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson’s disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. The Lancet Neurol 21:428–437. https://doi.org/10.1016/s1474-4422(22)00085-0
10.1016/s1474-4422(22)00085-0
[27]
Dafotakis M, Sparing R, Juzek A et al (2009) Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis. J Clin Neurosci 16:335–337. https://doi.org/10.1016/j.jocn.2008.02.015
10.1016/j.jocn.2008.02.015
[28]
Dafsari HS, Martinez-Martin P, Rizos A et al (2019) EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov Disord 34:353–365. https://doi.org/10.1002/mds.27626
10.1002/mds.27626
[29]
Dean MN, Standaert DG (2024) Levodopa infusion therapies for Parkinson disease. Curr Opin Neurol 37:409–413. https://doi.org/10.1097/wco.0000000000001277
10.1097/wco.0000000000001277
[30]
Denny AP, Behari M (1999) Motor fluctuations in Parkinson’s disease. J Neurol Sci 165:18–23. https://doi.org/10.1016/s0022-510x(99)00052-0
10.1016/s0022-510x(99)00052-0
[31]
Deuschl G, Follett KA, Luo P et al (2020) Comparing two randomized deep brain stimulation trials for Parkinson’s disease. J Neurosurg 132:1376–1384. https://doi.org/10.3171/2018.12.jns182042
10.3171/2018.12.jns182042
[32]
Diaconu Ş, Irincu L, Ţînţ D, Falup-Pecurariu C (2023) Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson’s disease. Front Neurol 14:1105650. https://doi.org/10.3389/fneur.2023.1105650
10.3389/fneur.2023.1105650
[33]
Ebersbach G, Poewe W (2018) „Medikamentös ausbehandelte Fluktuationen“ trotz „optimierter peroraler/transdermaler Therapie“ bei Morbus Parkinson: Versuch einer pragmatischen Definition. Aktuelle Neurol 45:665–671. https://doi.org/10.1055/a-0642-1737
10.1055/a-0642-1737
[34]
Ebersbach G, Höglinger GU, Koeglsperger T, Poewe W (2024) Zustandsschwankungen bei der Parkinson-Krankheit jenseits von On-/Off-Fluktuationen. Dgneurologie 7:453–460. https://doi.org/10.1007/s42451-024-00700-0
10.1007/s42451-024-00700-0
[35]
Elia AE, Dollenz C, Soliveri P, Albanese A (2012) Motor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulation. Eur J Neurol 19:76–83. https://doi.org/10.1111/j.1468-1331.2011.03437.x
10.1111/j.1468-1331.2011.03437.x
[36]
Espay AJ, Hauser RA, Dhall R et al (2024a) Safety and efficacy of IPX203 in Parkinson’s Disease: the RISE-PD open-label extension study. Mov Disord 39:428–432. https://doi.org/10.1002/mds.29685
10.1002/mds.29685
[37]
Espay AJ, Ostrem JL, Formella AE, Tanner CM (2024b) Extended-release amantadine for OFF-related dystonia in Parkinson’s disease. Park Relat Disord 122:106088. https://doi.org/10.1016/j.parkreldis.2024.106088
10.1016/j.parkreldis.2024.106088
[38]
Espay AJ, Stocchi F, Pahwa R et al (2024c) Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson’s disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol 23:465–476. https://doi.org/10.1016/s1474-4422(24)00052-8
10.1016/s1474-4422(24)00052-8
[39]
Fabbri M, Barbosa R, Rascol O (2023) Off-time Treatment options for Parkinson’s disease. Neurol Ther 12:391–424. https://doi.org/10.1007/s40120-022-00435-8
10.1007/s40120-022-00435-8
[40]
Fahn S (2015) The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord 30:4–18. https://doi.org/10.1002/mds.26102
10.1002/mds.26102
[41]
Fasano A, Romito LM, Daniele A et al (2010) Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants. Brain 133:2664–2676. https://doi.org/10.1093/brain/awq221
10.1093/brain/awq221
[42]
Fasano A, García-Ramos R, Gurevich T et al (2023) Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: long-term results from COSMOS. J Neurol 270:2765–2775. https://doi.org/10.1007/s00415-023-11615-3
10.1007/s00415-023-11615-3
[43]
Fernandez HH, Odin P, Standaert DG et al (2023) Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson’s disease continuum: Revelations from the MANAGE-PD validation cohort. Park Relat Disord 116:105514. https://doi.org/10.1016/j.parkreldis.2023.105514
10.1016/j.parkreldis.2023.105514
[44]
Fernández-Pajarín G, Sesar Á, Ares B et al (2021) Continuous subcutaneous apomorphine infusion before subthalamic deep brain stimulation: a prospective, comparative study in 20 patients. Mov Disord Clin Pract 8:1216–1224. https://doi.org/10.1002/mdc3.13338
10.1002/mdc3.13338
[45]
Ferreira JJ, Lees A, Rocha J-F et al (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15:154–165. https://doi.org/10.1016/s1474-4422(15)00336-1
10.1016/s1474-4422(15)00336-1
[46]
Ferreira JJ, Lees A, Rocha J-F et al (2019) Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol 26:953–960. https://doi.org/10.1111/ene.13914
10.1111/ene.13914
[47]
Fietzek UM, Messner M, Levin J (2023) Kann KI Parkinson? Nervenheilkunde 42:612–620. https://doi.org/10.1055/a-2133-1575
10.1055/a-2133-1575
[48]
Fiore S, Persichino L, Anticoli S, Pandis MFD (2014) A neuroleptic malignant-like syndrome (NMLS) in a patient with Parkinson’s disease resolved with rotigotine: a case report. Acta BioMed 85:281–284
[49]
Franke C, Storch A (2017) Chapter thirty-three nonmotor fluctuations in Parkinson’s disease. Int Rev Neurobiol 134:947–971. https://doi.org/10.1016/bs.irn.2017.05.021
10.1016/bs.irn.2017.05.021
[50]
Fujimiya M, Ataka K, Asakawa A et al (2011) Ghrelin, des-acyl ghrelin and obestatin on the gastrointestinal motility. Peptides 32:2348–2351. https://doi.org/10.1016/j.peptides.2011.07.020
10.1016/j.peptides.2011.07.020
Showing 50 of 129 references
Metrics
6
Citations
129
References
Details
- Published
- Mar 22, 2025
- Vol/Issue
- 133(2)
- Pages
- 347-359
- License
- View
Authors
Funding
Klinikum der Universität München
Cite This Article
Thomas Koeglsperger, Emir Berberovic, Christian Dresel, et al. (2025). Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations. Journal of Neural Transmission, 133(2), 347-359. https://doi.org/10.1007/s00702-025-02911-5
Related
You May Also Like
Astrocytes and Glioblastoma cells release exosomes carrying mtDNA
Michele Guescini, Susanna Genedani · 2009
549 citations
The IL-1β phenomena in neuroinflammatory diseases
Andrew S. Mendiola, Astrid E. Cardona · 2017
276 citations
Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder
Thomas Dresler, Anne Guhn · 2012
167 citations